Comparative oncology evaluation of intravenous recombinant oncolytic vesicular stomatitis virus therapy in spontaneous canine cancer

Shruthi Naik, Gina D. Galyon, Nathan J. Jenks, Michael B. Steele, Amber C. Miller, Sara D. Allstadt, Lukkana Suksanpaisan, Kah-Whye Peng, Mark J Federspiel, Stephen J Russell, Amy K. LeBlanc

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Clinical translation of intravenous therapies to treat disseminated or metastatic cancer is imperative. Comparative oncology, the evaluation of novel cancer therapies in animals with spontaneous cancer, can be utilized to inform and accelerate clinical translation. Preclinical murine studies demonstrate that single-shot systemic therapy with a vesicular stomatitis virus (VSV)-IFNβ-NIS, a novel recombinant oncolytic VSV, can induce curative remission in tumor-bearing mice. Clinical translation of VSV-IFNβ-NIS therapy is dependent on comprehensive assessment of clinical toxicities, virus shedding, pharmacokinetics, and efficacy in clinically relevant models. Dogs spontaneously develop cancer with comparable etiology, clinical progression, and response to therapy as human malignancies. A comparative oncology study was carried out to investigate feasibility and tolerability of intravenous oncolytic VSVIFNβ- NIS therapy in pet dogs with spontaneous cancer. Nine dogs with various malignancies were treated with a single intravenous dose of VSV-IFNβ-NIS. Two dogs with high-grade peripheral T-cell lymphoma had rapid but transient remission of disseminated disease and transient hepatotoxicity that resolved spontaneously. There was no shedding of infectious virus. Correlative pharmacokinetic studies revealed elevated levels of VSV RNA in blood in dogs with measurable disease remission. This is the first evaluation of intravenous oncolytic virus therapy for spontaneous canine cancer, demonstrating that VSV-IFNβ-NIS is well-tolerated and safe in dogs with advanced or metastatic disease. This approach has informed clinical translation, including dose and target indication selection, leading to a clinical investigation of intravenous VSVIFNβ- NIS therapy, and provided preliminary evidence of clinical efficacy and potential biomarkers that correlate with therapeutic response.

Original languageEnglish (US)
Pages (from-to)316-326
Number of pages11
JournalMolecular Cancer Therapeutics
Volume17
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Vesicular Stomatitis
Canidae
Viruses
Dogs
Neoplasms
Virus Shedding
Therapeutics
Animal Assisted Therapy
Oncolytic Virotherapy
Pharmacokinetics
Peripheral T-Cell Lymphoma
RNA Viruses
Non-Hodgkin's Lymphoma
Biomarkers

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Comparative oncology evaluation of intravenous recombinant oncolytic vesicular stomatitis virus therapy in spontaneous canine cancer. / Naik, Shruthi; Galyon, Gina D.; Jenks, Nathan J.; Steele, Michael B.; Miller, Amber C.; Allstadt, Sara D.; Suksanpaisan, Lukkana; Peng, Kah-Whye; Federspiel, Mark J; Russell, Stephen J; LeBlanc, Amy K.

In: Molecular Cancer Therapeutics, Vol. 17, No. 1, 01.01.2018, p. 316-326.

Research output: Contribution to journalArticle

Naik, Shruthi ; Galyon, Gina D. ; Jenks, Nathan J. ; Steele, Michael B. ; Miller, Amber C. ; Allstadt, Sara D. ; Suksanpaisan, Lukkana ; Peng, Kah-Whye ; Federspiel, Mark J ; Russell, Stephen J ; LeBlanc, Amy K. / Comparative oncology evaluation of intravenous recombinant oncolytic vesicular stomatitis virus therapy in spontaneous canine cancer. In: Molecular Cancer Therapeutics. 2018 ; Vol. 17, No. 1. pp. 316-326.
@article{79d928c7b69542e189d2423409ba24c9,
title = "Comparative oncology evaluation of intravenous recombinant oncolytic vesicular stomatitis virus therapy in spontaneous canine cancer",
abstract = "Clinical translation of intravenous therapies to treat disseminated or metastatic cancer is imperative. Comparative oncology, the evaluation of novel cancer therapies in animals with spontaneous cancer, can be utilized to inform and accelerate clinical translation. Preclinical murine studies demonstrate that single-shot systemic therapy with a vesicular stomatitis virus (VSV)-IFNβ-NIS, a novel recombinant oncolytic VSV, can induce curative remission in tumor-bearing mice. Clinical translation of VSV-IFNβ-NIS therapy is dependent on comprehensive assessment of clinical toxicities, virus shedding, pharmacokinetics, and efficacy in clinically relevant models. Dogs spontaneously develop cancer with comparable etiology, clinical progression, and response to therapy as human malignancies. A comparative oncology study was carried out to investigate feasibility and tolerability of intravenous oncolytic VSVIFNβ- NIS therapy in pet dogs with spontaneous cancer. Nine dogs with various malignancies were treated with a single intravenous dose of VSV-IFNβ-NIS. Two dogs with high-grade peripheral T-cell lymphoma had rapid but transient remission of disseminated disease and transient hepatotoxicity that resolved spontaneously. There was no shedding of infectious virus. Correlative pharmacokinetic studies revealed elevated levels of VSV RNA in blood in dogs with measurable disease remission. This is the first evaluation of intravenous oncolytic virus therapy for spontaneous canine cancer, demonstrating that VSV-IFNβ-NIS is well-tolerated and safe in dogs with advanced or metastatic disease. This approach has informed clinical translation, including dose and target indication selection, leading to a clinical investigation of intravenous VSVIFNβ- NIS therapy, and provided preliminary evidence of clinical efficacy and potential biomarkers that correlate with therapeutic response.",
author = "Shruthi Naik and Galyon, {Gina D.} and Jenks, {Nathan J.} and Steele, {Michael B.} and Miller, {Amber C.} and Allstadt, {Sara D.} and Lukkana Suksanpaisan and Kah-Whye Peng and Federspiel, {Mark J} and Russell, {Stephen J} and LeBlanc, {Amy K.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1158/1535-7163.MCT-17-0432",
language = "English (US)",
volume = "17",
pages = "316--326",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Comparative oncology evaluation of intravenous recombinant oncolytic vesicular stomatitis virus therapy in spontaneous canine cancer

AU - Naik, Shruthi

AU - Galyon, Gina D.

AU - Jenks, Nathan J.

AU - Steele, Michael B.

AU - Miller, Amber C.

AU - Allstadt, Sara D.

AU - Suksanpaisan, Lukkana

AU - Peng, Kah-Whye

AU - Federspiel, Mark J

AU - Russell, Stephen J

AU - LeBlanc, Amy K.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Clinical translation of intravenous therapies to treat disseminated or metastatic cancer is imperative. Comparative oncology, the evaluation of novel cancer therapies in animals with spontaneous cancer, can be utilized to inform and accelerate clinical translation. Preclinical murine studies demonstrate that single-shot systemic therapy with a vesicular stomatitis virus (VSV)-IFNβ-NIS, a novel recombinant oncolytic VSV, can induce curative remission in tumor-bearing mice. Clinical translation of VSV-IFNβ-NIS therapy is dependent on comprehensive assessment of clinical toxicities, virus shedding, pharmacokinetics, and efficacy in clinically relevant models. Dogs spontaneously develop cancer with comparable etiology, clinical progression, and response to therapy as human malignancies. A comparative oncology study was carried out to investigate feasibility and tolerability of intravenous oncolytic VSVIFNβ- NIS therapy in pet dogs with spontaneous cancer. Nine dogs with various malignancies were treated with a single intravenous dose of VSV-IFNβ-NIS. Two dogs with high-grade peripheral T-cell lymphoma had rapid but transient remission of disseminated disease and transient hepatotoxicity that resolved spontaneously. There was no shedding of infectious virus. Correlative pharmacokinetic studies revealed elevated levels of VSV RNA in blood in dogs with measurable disease remission. This is the first evaluation of intravenous oncolytic virus therapy for spontaneous canine cancer, demonstrating that VSV-IFNβ-NIS is well-tolerated and safe in dogs with advanced or metastatic disease. This approach has informed clinical translation, including dose and target indication selection, leading to a clinical investigation of intravenous VSVIFNβ- NIS therapy, and provided preliminary evidence of clinical efficacy and potential biomarkers that correlate with therapeutic response.

AB - Clinical translation of intravenous therapies to treat disseminated or metastatic cancer is imperative. Comparative oncology, the evaluation of novel cancer therapies in animals with spontaneous cancer, can be utilized to inform and accelerate clinical translation. Preclinical murine studies demonstrate that single-shot systemic therapy with a vesicular stomatitis virus (VSV)-IFNβ-NIS, a novel recombinant oncolytic VSV, can induce curative remission in tumor-bearing mice. Clinical translation of VSV-IFNβ-NIS therapy is dependent on comprehensive assessment of clinical toxicities, virus shedding, pharmacokinetics, and efficacy in clinically relevant models. Dogs spontaneously develop cancer with comparable etiology, clinical progression, and response to therapy as human malignancies. A comparative oncology study was carried out to investigate feasibility and tolerability of intravenous oncolytic VSVIFNβ- NIS therapy in pet dogs with spontaneous cancer. Nine dogs with various malignancies were treated with a single intravenous dose of VSV-IFNβ-NIS. Two dogs with high-grade peripheral T-cell lymphoma had rapid but transient remission of disseminated disease and transient hepatotoxicity that resolved spontaneously. There was no shedding of infectious virus. Correlative pharmacokinetic studies revealed elevated levels of VSV RNA in blood in dogs with measurable disease remission. This is the first evaluation of intravenous oncolytic virus therapy for spontaneous canine cancer, demonstrating that VSV-IFNβ-NIS is well-tolerated and safe in dogs with advanced or metastatic disease. This approach has informed clinical translation, including dose and target indication selection, leading to a clinical investigation of intravenous VSVIFNβ- NIS therapy, and provided preliminary evidence of clinical efficacy and potential biomarkers that correlate with therapeutic response.

UR - http://www.scopus.com/inward/record.url?scp=85040087138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040087138&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-17-0432

DO - 10.1158/1535-7163.MCT-17-0432

M3 - Article

VL - 17

SP - 316

EP - 326

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 1

ER -